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Prioritizing Primary Prevention Strategies for Cardiovascular Disease at the 
Clinic Population Level 
Giulio C. Rottaro Castejon, Bradley Richards, and Brita Roy. Section of 
General Internal Medicine, Department of Medicine, Yale University School 
of Medicine, New Haven, CT 
 
Cardiovascular Disease remains the number one cause of mortality in the United 
States with atherosclerotic cardiovascular disease (ASCVD) being a major component. 
Lifestyle interventions remain the first line treatment for the prevention of ASCVD, and clinic-
based interventions effectively improve rates of healthy lifestyle choices. However, these 
programs require additional resources and there is currently no guidance for clinic directors 
to understand what lifestyle intervention(s) have the highest value for their unique 
population. We propose a novel application of the 10-year ASCVD risk calculator to a clinic 
patient cohort, thereby acting as a tool for providers and administrators to develop lifestyle 
intervention programs that will have the greatest risk reduction for their clinic population. 	
We first defined the ASCVD 10-year risk for patient cohorts from four different 
primary care clinics in New Haven, CT by normalizing and aggregating individual patient 10-
year ASCVD risk scores. We then calculated changes to this normalized aggregate risk by 
modeling the effects of evidence-based interventions found in Cochrane Reviews of different 
efficacy to each of four modifiable risk factors used in the 10-year ASCVD risk calculator. 
The four different modifiable risk factors include systolic blood pressure, total cholesterol, 
HDL cholesterol and smoking status. A resulting change in each cohort’s normalized 
aggregate risk was calculated. 	
The clinic cohorts had different levels of modeled risk reduction from the same 
interventions. The magnitude of reduction was dependent on baseline normalized aggregate 
risk and prevalence of risk factor(s) targeted in the interventions. The three clinics where the 
baseline normalized aggregate risk was above 100 events per 1,000, patients had a greater 
risk reduction from an organizational intervention aimed at improving the quality of treatment 
for hypertensive patients compared to all other evidence-based interventions found in 
Cochrane Reviews. In the clinic that had a lower baseline normalized aggregate risk, the 
highest yield intervention was dietary advice by providers. Our data demonstrate that the 
highest yield lifestyle intervention for any clinic may vary depending on the makeup of the 
populations and its risk factors. 
The tool created in this study can be used by clinic providers and administrators to 
estimate the effects of various interventions on the ASCVD risk of their clinic cohort. The 
models generated by this tool can be used to guide strategy and prioritize clinic resources 
based on the extrapolated effects of evidence based interventions to specific clinic 
populations. Furthermore, it may also guide interventions planned to address needs 
identified by community health assessments. Because the tool predicts outcomes for 
specific patient populations it has the potential to foster the application of evidence-based 
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The 2013 American College of Cardiology and American Heart Association 
(ACC/AHA) Guideline on Lifestyle Management to Reduce Cardiovascular Risk 
emphasized lifestyle interventions as a crucial component of cardiovascular disease 
prevention.1 These guidelines recommend that providers target poor dietary habits, 
and physical inactivity given both their prevalence on the general population and 
their indirect, yet significant, effect on cardiovascular disease risk.1 Interventions 
mentioned in this report include advice to engage in physical activity two to three 
times per week, advice to decrease daily sodium intake, advice to follow specific diet 
plans available to the public, etc. The effect of such lifestyle interventions varies by 
patient, and the intervention with this highest cardiovascular risk reduction is 
determined by a patient’s risk factors.2 These interventions are variable in resource 
requirements for implementation, but the most effective ones generally require more 
resources. As such, it is cost-prohibitive for clinics to make all evidence-based 
lifestyle interventions available to their patients.3  
Given the high prevalence of modifiable behaviors contributing to 
cardiovascular disease risk and the cost of lifestyle interventions there is both a 
clinical and financial argument to approach primary cardiovascular disease 
prevention at the population level.4 In a 2011 article by Dr. Thomas A. Pearson, he 
described the need for both a clinical and population approach to the primary 
prevention of cardiovascular disease.4 He went on to say that much of the decline in 
cardiovascular mortality over the 20th century was from lifestyle changes in the 
American population. Clinics should focus primary prevention efforts on the lifestyle 
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interventions with the greatest potential risk reduction.2,5 However, the evidence 
available on lifestyle interventions is generalized and may not be applicable across 
all clinic populations.4 For example, smoking cessation programs have been 
reported to be the most cost-effective intervention for cardiovascular disease 
prevention.5 But, in a population with a low prevalence of smoking, these 
interventions will be less effective in reducing total risk of cardiovascular disease. 
There currently is no method for clinics to quantitatively estimate the expected 
effects of published interventions on their population’s cardiovascular risk and 
compare interventions against each other. 
The 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to 
Reduce Atherosclerotic Cardiovascular Risk in Adults included a robust risk 
calculation model to inform individual level medical decision-making to reduce the 
risk of events from atherosclerotic disease.6 This model includes modifiable risk 
factors such as lipids levels, blood pressure, and smoking status. In this study, we 
explored the use of the ACC/AHA 10-year atherosclerotic cardiovascular disease 
(ASCVD) risk calculator as a predictive model to aid in primary disease prevention 
strategies at the clinic level. We hypothesized that this model could be modified to 
calculate the risk of ASCVD for an entire clinic cohort using data from electronic 
health records (EHR). Furthermore, we hypothesized that the effects of lifestyle 
interventions on modifiable risk factors can be incorporated in the predictive model 
to quantitatively estimate their effect on cohort-wide ASCVD prevention. The tool is 
meant to empower individual clinics to estimate the effectiveness of different 
evidence-based interventions in the primary prevention of ASCVD. 
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Statement of Purpose 
The main goal of this study was to create a novel tool that applies the 10-year 
ASCVD Risk Calculator to a clinic population to guide primary preventative 
strategies for clinic-based patient cohorts. The tool calculated baseline ASCVD risk 
for each cohort and estimated the number of prevented ASCVD events for different 
interventions. We hypothesized that each cohort would respond differently to the 
same interventions, and thus the highest value intervention for a given cohort would 
vary depending on the demographics and the rates and distribution of clinical risk 
factors. In this study, we first applied the tool to randomly generated cohorts 
developing a simulation model as a proof of concept that the magnitude of 
cardiovascular event reduction in response to a given lifestyle modification strategy 
varies depending on the baseline risk of the population. Then we applied the tool to 
four real-world clinic cohorts and extrapolated the effects of several interventions. 
Ultimately, this tool may allow primary care clinics to implement the highest yield 
intervention for primary ASCVD prevention. This study focused mostly on the theory 
and development of such a guidance tool but did not proceed to implementation. 
Methods 
To study the differential effects of lifestyle modifications on diverse patient 
cohorts, we used a three-step analytic approach. First we developed a series of 
mathematical models to create a tool to test hypothetical treatment effects using the 
10-year ASCVD risk calculator. We then applied the tool to randomly generated 
cohorts as a simulation to demonstrate the concept. These randomly generated 
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cohorts were designed to appear statistically indistinguishable but to have different 
baseline ASCVD risks, thereby being less likely to respond differently to intervention. 
Lastly we applied the tool to four real-world clinic cohorts. In this last application we 
also extrapolated the effects of non-pharmacologic interventions to determine which 
intervention is the best for any given cohort. 
Model: Baseline 10-Year ASCVD Risk and Risk Change Equations 
We created an algorithm that uses data that can be extracted from EHR 
systems to calculate a baseline 10-year ASCVD risk for each patient using the 
statistical model from the 2013 ACC/AHA guidelines.6 For an individual, i, the 10-
year ASCVD risk is represented by ri which is a function of age, gender, race, total 
cholesterol (TC), HDL cholesterol (HDL), systolic blood pressure (SBP), diagnosis of 
diabetes mellitus (DM), whether or not they are receiving hypertension treatment 
(HTN), and whether or not they smoke (S). 
 
𝑟% = 𝑓()*+, 𝑎𝑔𝑒%, 𝑔𝑒𝑛𝑑𝑒𝑟%, 𝑟𝑎𝑐𝑒%, 𝑇𝐶%, 𝐻𝐷𝐿%, 𝑆𝐵𝑃%, 𝐷𝑀%, 𝐻𝑇𝑁%, 𝑆%  
 
Given the limitations of this model the individual risk scores are bounded 
between 1% and 30%. We add the calculated individual risk scores for a cohort (C) 
to get the expected number of ASCVD events in 10 years (RC), also referred to as 





This value can be normalized to get the number of predicted ASCVD events 
in the next ten years per 1,000 patients, or normalized aggregate risk. 
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Equation 1. Normalized aggregate risk given in number of expected ASCVD 





Using this method to obtain the normalized aggregate risk, we can directly 
calculate how changes in the modifiable risk factors will affect the number of 
expected ASCVD events in the next 10 years. In other words, we can directly 
calculate the number of prevented ASCVD events from an intervention on a clinic 
population. Conversely, we can quantify the required changes to a modifiable risk 
factor in order to achieve a specific level of reduction in the number of expected 
ASCVD events. 
Changes in total cholesterol are represented by the average decrease in 
total cholesterol (∆𝑇𝐶) applied to all individuals with a 10-year ASCVD risk of 7.5% 
or higher per ACC/AHA guidelines. Using these principles, the tool can calculate the 
changes to individual risk scores. 
 
∆𝑟% = 0,  if  𝑟% < 0.075 
 
∆𝑟% = 𝑓()*+, 𝑎𝑔𝑒%, 𝑔𝑒𝑛𝑑𝑒𝑟%, 𝑟𝑎𝑐𝑒%, 𝑀𝑎𝑥 𝑇𝐶% − ∆𝑇𝐶, 100 , 𝐻𝐷𝐿%, 𝑆𝐵𝑃%, 𝐷𝑀%, 𝐻𝑇𝑁%, 𝑆% − 	𝑟%, 
 if  𝑟% ≥ 0.075 
 
Note that the final total cholesterol (𝑇𝐶% − ∆𝑇𝐶) is bounded from below by 100 
mg/dL to simulate the real-life limitations of cholesterol lowering therapies. Using 
these changes to individual risk scores the tool can then set up an equation for 
change in normalized aggregate risk, ∆𝑅*. 
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These sets of equations provide a direct relationship between changes to the 
total cholesterol and the normalized aggregate risk scores. The equations can be 
used to directly calculate the number of prevented ASCVD events per 1,000 patients 
for the expected population level change in cholesterol from a given intervention 
aiming to reduce total cholesterol. For any given cohort ∆𝑅* was calculated for a 
range of ∆𝑇𝐶 values from 0 mg/dL to 150 mg/dL by increments of 1 mg/dL. 
Changes in HDL Cholesterol are represented by the average increase in 
HDL Cholesterol (∆HDL) to all individuals. In this case the change in individual risk 
score is given by this equation: 
 
∆𝑟% = 𝑓()*+, 𝑎𝑔𝑒%, 𝑔𝑒𝑛𝑑𝑒𝑟%, 𝑟𝑎𝑐𝑒%, 𝑇𝐶%, 𝐻𝐷𝐿% + ∆𝐻𝐷𝐿, 𝑆𝐵𝑃%, 𝐷𝑀%, 𝐻𝑇𝑁%, 𝑆% − 	𝑟% 
 
Similar to total cholesterol, these equations can be used to directly calculate 
the number of prevented ASCVD events per 1,000 patients for a given intervention 
on HDL cholesterol. For any given cohort ∆𝑅* was calculated for a range of ∆𝐻𝐷𝐿 
values from 0 mg/dL to 100 mg/dL by increments of 1 mg/dL. 
Changes in systolic blood pressure are represented by the decrease in 
systolic blood pressure for all individuals under 60 years of age with a systolic blood 
pressure above 140 mmHg and all individuals over 60 years of age with a systolic 
blood pressure above 150 mmHg. These rules were adapted from the Eighth Joint 
National Committee guidelines.7 Like the total cholesterol model, we have limited the 
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final systolic blood pressure (𝑆𝐵𝑃% − ∆𝑆𝐵𝑃) to a lower bound of 110 mmHg for 
treated individuals. The individual changes in risk scores are given by: 
 
∆𝑟% = 𝑓()*+, 𝑎𝑔𝑒%, 𝑔𝑒𝑛𝑑𝑒𝑟%, 𝑟𝑎𝑐𝑒%, 𝑇𝐶%, 𝐻𝐷𝐿%,𝑀𝑎𝑥 𝑆𝐵𝑃% − ∆𝑆𝐵𝑃, 110 , 𝐷𝑀%, 𝑇𝑅𝑈𝐸, 𝑆% − 	𝑟%, 
if  𝑆𝐵𝑃% > 140 and 𝑎𝑔𝑒% < 60, or 𝑆𝐵𝑃% > 150 and 𝑎𝑔𝑒% ≥ 60 
 
∆𝑟% = 0, otherwise. 
 
As done previously, these equations can be used to directly calculate the 
number of prevented ASCVD events per 1,000 patients for a given intervention on 
systolic blood pressure. For any given cohort ∆𝑅* was calculated for range of ∆𝑆𝐵𝑃 
values from 0 mmHg to 80 mmHg by increments of 1 mmHg. 
 
Smoking status is a Boolean variable, so interventions are modeled by a 
probability of smoking cessation. Using a probability of smoking cessation, we model 
the risk score using conditional probability. 
We define 𝑟%,)* as the risk for patient i without smoking but leave all other risk 
factors unchanged. It is given by: 
𝑟%,)* = 𝑓()*+, 𝑎𝑔𝑒%, 𝑔𝑒𝑛𝑑𝑒𝑟%, 𝑟𝑎𝑐𝑒%, 𝑇𝐶%, 𝐻𝐷𝐿%,𝑀𝑎𝑥 𝑆𝐵𝑃% − ∆𝑆𝐵𝑃, 120 , 𝐷𝑀%, 𝐻𝑇𝑁%, 𝐹𝐴𝐿𝑆𝐸  
 
Using conditional probability, we can calculate a new risk score (𝑟%,^) given a 
probability (𝑝)*) that any given patient will quit. 
𝑟%,^ = 𝑟%,)*×𝑝)* + 𝑟%× 1 − 𝑝`a  
Which implies: 
∆𝑟% = 𝑟%,)*×𝑝)* − 𝑟%×𝑝`a = 𝑝)*(𝑟%,)* − 𝑟%) 
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Note that if the patient is not a smoker, 𝑟%,)* is equal to 𝑟% and therefore ∆𝑟% 
becomes zero. Furthermore, we can use this same principle with the whole cohort 
and get the following equation. 




𝑝)*(𝑅*,)* − 𝑅*) 
Note that the last equation reveals a direct linear relationship between ∆𝑅a and 
the probability and smoking cessation, 𝑝)*, making this calculation remarkably 
simpler than all other. For any given cohort ∆𝑅* was calculated for range of 𝑝)* 
values from 0.00 to 1.00 by increments of 0.01. 
All the different numerical methods discussed were used to calculate changes 
to ∆𝑅* based on changes to a single variable. However, they can also be combined 
to calculate ∆𝑅*for any multifactorial intervention such as lifestyle interventions that 
may have effects on all modifiable risk factors. 
Simulation: Randomly Generated Patient Cohorts for Proof of Concept 
For development and proof of concept we first aimed to show how 
populations with the same demographics and similar risk factors can have drastically 
different baseline aggregate ASCVD risk and sub-sequentially drastically different 
responses to risk factor modifications. Therefore, randomly generated patient 
cohorts were created using the same probability distribution for all variables across 
all patients and cohorts. The randomly generated cohorts were 300 patients in size. 
This sample size was chosen because it is large enough to apply the law of large 
numbers, yet small enough to still show variability from population to population. 
 14 
Furthermore, a patient panel size of 300 patients is within the normal limits for a 
single primary care provider.  The distribution of the variables is shown in Table 1. 







Total	Cholesterol	(mg/dL) Normal	distribution	(𝜇 = 182, 𝜎 = 44)	with	
a	lower	boundary	of	58	










The numbers used to set the mean and standard deviation for total 
cholesterol, HDL cholesterol, and systolic blood pressure were based on baseline 
numbers from all patients included in analyses of local clinic cohorts described in a 
later section (Application: Selection of Local Clinic Cohorts). The percentages of 
gender, race, diabetes incidence, smoking incidence and hypertension treatment 
incidence were based on the same clinic populations. Given that the 10-Year 
ASCVD Risk Calculator can only use two sets of coefficients for race, white/other 
and black, no other races were included in the randomly generated patient 
populations. The cohorts were randomly generated and therefore may be statistically 
different from each other if the means or percentages were compared. To create 
cohorts that are statistically indistinguishable, all cohorts with a statistically 
significant difference in mean age, total cholesterol, HDL cholesterol or systolic 
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blood pressure or a statistically significant difference in percentage of males, black 
patients, diabetes incidence, smoking incidence or hypertension treatment incidence 
(using a two-tailed z-test with a p-value of 5%) were discarded and replaced with 
new randomly generated cohorts.  
Simulation: Variance in Baseline Risk of Randomly Generated Cohorts 
We randomly generated ten thousand cohorts that were statistically 
indistinguishable from each other. Using Equation 1, the normalized aggregate risk 
was calculated for each of these cohorts. The results were displayed in a histogram 
(Figure 1) to show the variation in normalized aggregate risk for statistically 
indistinguishable populations. 
Simulation: Variance in Sensitivity to Interventions of Randomly 
Generated Cohorts 
We created another 10 randomly generated cohorts using the same 
methodology. Once again, these cohorts were statistically indistinguishable based 
on two-tailed Z-test with a p-value of 5%. We subjected these ten clinic cohorts to a 
range of changes to the modifiable risk factors and the resulting change in 
normalized aggregate risk was calculated. The methods by which we calculated the 
change in normalized aggregate risk was described in a previous section (To study 
the differential effects of lifestyle modifications on diverse patient cohorts, we used a 
three-step analytic approach. First we developed a series of mathematical models to 
create a tool to test hypothetical treatment effects using the 10-year ASCVD risk 
calculator. We then applied the tool to randomly generated cohorts as a simulation 
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to demonstrate the concept. These randomly generated cohorts were designed to 
appear statistically indistinguishable but to have different baseline ASCVD risks, 
thereby being less likely to respond differently to intervention. Lastly we applied the 
tool to four real-world clinic cohorts. In this last application we also extrapolated the 
effects of non-pharmacologic interventions to determine which intervention is the 
best for any given cohort. 
Model: Baseline 10-Year ASCVD Risk and Risk Change Equations). The 
modifiable risk factors we tested were total cholesterol, HDL cholesterol, systolic 
blood pressure and smoking status. 
Application: Selection of Local Clinic Cohorts 
We intentionally selected four adult primary care clinics in the greater New 
Haven, CT area that each serve a unique population with a different demographic 
makeup. The first clinic we selected was the primary care internal medicine 
residency clinic (SRC), which has a high percentage of Medicaid and African 
American patients. The second clinic we selected was the categorical internal 
medicine residency program clinic (PCC) which is similar in demographic distribution 
to the SRC but larger in size. The third clinic we selected was the student-run 
HAVEN Free Clinic (HAVEN), which serves mostly uninsured, undocumented 
immigrants from Latin America. The fourth clinic we selected was Yale Internal 
Medicine Associates (YIMA), a general internal medicine clinic that serves a larger 
percentage of white patients and a lower percentage of Medicaid and uninsured 
patients compared to the other clinics selected. All the participating clinics shared 
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the same hospital-wide electronic health record (EHR) system (EPIC ™) from which 
patient demographic and clinical data was pulled. 
For each clinic, patients younger than 40 years of age or older than or equal 
to 80 years of age were excluded. Patients who had been reported as deceased on 
the EHR were also excluded. Patients who had not visited the clinic to which they 
were assigned between January 1st, 2014 and January 1st, 2016 were also excluded 
to limit the clinic populations to the patients who are most likely to identify a 
physician in that clinic as their primary care provider. Patients with a prior ASCVD 
event based on International Classification of Diseases (ICD) 9 and 10 codes were 
also excluded from analysis as the ASCVD risk calculator is not designed to predict 
their risk. Patients without a systolic blood pressure, total cholesterol, HDL 
cholesterol were considered to have incomplete data and excluded from analysis. 
 
Table 2. Description of patient selection process by clinic cohort. 
		 PCC	 SRC	 HAVEN	 YIMA	
Starting	Count	 9164	 4401	 506	 5859	
Removed	for:	 		 		 		 		
Out	of	age	range	 3619	 1261	 292	 1671	
Deceased	 173	 86	 0	 124	
Not	recently	seen	 908	 365	 83	 642	
Previous	ASCVD	 680	 494	 2	 451	
Incomplete	Data	 2653	 734	 88	 1046	
Final	Patient	Count	 1131	 1461	 41	 1925	
 
Data on 19,930 patients from the four different clinic sites were extracted from 
the shared electronic health record. Of these patients 10,851 had to be removed for 
meeting study criteria such as being under the age of 40, over the age of 80, 
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deceased, or having a prior history of ASCVD. Of the remaining patients, 4,521 had 
missing data such as a valid systolic blood pressure, total cholesterol or HDL 
cholesterol. A clinic by clinic breakdown can be found on Table 2. 
Application: Independent Variables from Clinic Cohorts 
For all patients, the most recent total cholesterol and HDL cholesterol on 
record were used for risk calculations. For each patient included, the systolic blood 
pressure used in the risk calculation was an average of all systolic blood pressures 
found in the EHR for the 2015 calendar year. Blood pressure data collected from an 
emergency department were excluded from the analysis, however data from non-
primary care ambulatory visits (e.g., cardiology clinic) or inpatient hospitalizations 
were included. A secondary analysis was performed using only the latest recorded 
systolic blood pressure.  
Treatment for hypertension was based on the list of active outpatient 
medications for any given patient. If a patient had at least one antihypertensive 
agent in their medication list, they were considered to be receiving hypertension 
treatment. The list of medications considered to be antihypertensive agents was 
based on the drug classes listed in Table 3. 







Diabetes diagnosis was based on a patient’s diagnosis list, problem list, or 
Hemoglobin A1c. Any patient with an ICD 9 or ICD 10 code associated with diabetes 
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mellitus type 1 or type 2 diagnosis was considered to have diabetes mellitus for their 
risk calculation. Any patient who ever had a hemoglobin A1c greater than 6.5% was 
also considered to have diabetes mellitus for risk calculation.  
The EHR has a variable for smoking status associated with every patient 
encounter. For the purpose of risk calculation, the smoking status was taken from a 
patient’s last encounter. Any patient who identified as a smoker regardless of 
quantity or method was labeled as a smoker. For patients who were former smokers 
the amount of time since they last smoked was not taken into consideration. 
Within all cohorts, there were patients with incomplete information, such as a 
lack of blood pressures in the past year or a lack of cholesterol lab data. For these 
patients, it was not possible to calculate a baseline 10-year ASCVD risk or to 
estimate the effect of any interventions, therefore they were excluded from the final 
analysis. The demographic data of patients with missing data was compared against 
the data of patient that were included in the final analysis for each individual cohort 
using a student’s T-test or a Chi Square Test of Independence with Yate’s 
Correction to calculate p-values. 
Application: Analysis of Clinic Cohorts 
We calculated the baseline normalized aggregate risk for the four clinic 
cohorts with Equation 1 using the data from patients who met inclusion criteria and 
had complete information. These four clinic cohorts were then subjected to a range 
of changes to the four modifiable risk factors. The ranges used and the calculation of 
the change in normalized aggregate risk were described in a previous section. (To 
study the differential effects of lifestyle modifications on diverse patient cohorts, we 
 20 
used a three-step analytic approach. First we developed a series of mathematical 
models to create a tool to test hypothetical treatment effects using the 10-year 
ASCVD risk calculator. We then applied the tool to randomly generated cohorts as a 
simulation to demonstrate the concept. These randomly generated cohorts were 
designed to appear statistically indistinguishable but to have different baseline 
ASCVD risks, thereby being less likely to respond differently to intervention. Lastly 
we applied the tool to four real-world clinic cohorts. In this last application we also 
extrapolated the effects of non-pharmacologic interventions to determine which 
intervention is the best for any given cohort. 
Model: Baseline 10-Year ASCVD Risk and Risk Change Equations) The 
modifiable risk factors tested were total cholesterol, HDL cholesterol, systolic blood 
pressure and smoking status. 
Application: Effect of Quality Improvement Interventions 
We conducted a literature search of Cochrane Review Articles for non-
pharmacologic interventions that affected any of the four modifiable risk factors in 
the 10-year ASCVD risk calculator, systolic blood pressure, total cholesterol, HDL 
cholesterol and smoking status. From these reviews, we extracted the effect size on 
the modifiable risk factor if it was shown to be statistically significant. For each 
intervention, we then applied the effect onto each patient who would have met the 
inclusion criteria for the intervention and calculated a new normalized aggregate risk 
score. 
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Statement of Contributions 
The original concept for the development of this tool was theorized by Dr. 
Michael Robert O’Brien during his first year as a Robert Wood Johnson Clinical 
Scholar. Early prototypes of the tool to calculate baseline 10-year ASCVD risk were 
developed by Giulio C. Rottaro and Jinyi Zhu. The literature search, proposal, 
development, and data analysis were conducted by Giulio C. Rottaro under the 
guidance of Dr. Bradley Richards and Dr. Brita Roy. Raw data was collected directly 
from the electronic health records system by the Yale Joint Data Analytics Team. 
The protocol was reviewed and approved by the Yale University Human 
Investigation Committee (Protocol number 1601017016). 
Results 
Simulation: Variance in Baseline Risk of Randomly Generated Cohorts 
The average normalized aggregate risk for these cohorts was 124.7 events 
per 1,000 patients in 10 years. The standard deviation was 4.8 events per 1,000 
patients in 10 years. Of the 10,000 cohorts, 464 had a normalized aggregate risk 
score that was outside of a 95% confidence interval set by the previously mentioned 
mean and standard deviation. The distribution of all 10,000 normalized aggregate 







Figure 1. Histogram of normalized aggregate risk for 10,000 randomly 




Simulation: Variance in Sensitivity to Interventions of Randomly 
Generated Cohorts 
	
Figure 2. Variances in sensitivity to total cholesterol decreases for randomly 
generated cohorts. Each color represents a different randomly generated cohort. 
Decreases in normalized aggregate risk of ASCVD events are displayed in expected 
ASCVD events per 1,000 patients in the next 10 years. 
The mean normalized aggregate risk score for ten randomly generated 
cohorts was 123 events per 1,000 patients in 10 years (range: 116-132). Figure 2 
shows the decrease in normalized aggregate risk for all ten cohorts resulting from 
total cholesterol decreases from 0 to 150 mg/dL applied to patients with a baseline 
risk above 7.5%. At 150 mg/dL, the mean decrease in normalized aggregate risk 
was 20.5 ASCVD events per 1,000 patients with a standard deviation of 1.7 events. 
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Figure 3 shows the decrease in normalized aggregate risk for all ten cohorts 
resulting from HDL cholesterol increases from 0 to 100 mg/dL applied to all patients. 
At 100 mg/dL, the mean decrease in normalized aggregate risk was 31.4 ASCVD 
events per 1,000 patients with a standard deviation of 2.5 events. 
	
Figure 3. Variances in sensitivity to HDL cholesterol increases for randomly 
generated cohorts. Each color represents a different randomly generated cohort. 
Decreases in normalized aggregate risk of ASCVD events are displayed in expected 
ASCVD events per 1,000 patients in the next 10 years. 
Figure 4 shows the decrease in normalized aggregate risk for all ten cohorts 
resulting from systolic blood pressure decreases from 0 to 80 mmHg applied to 
patients who qualified for intervention. The intervention was only applied to patients 
who met criteria as described in a previous section. (To study the differential effects 
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of lifestyle modifications on diverse patient cohorts, we used a three-step analytic 
approach. First we developed a series of mathematical models to create a tool to 
test hypothetical treatment effects using the 10-year ASCVD risk calculator. We then 
applied the tool to randomly generated cohorts as a simulation to demonstrate the 
concept. These randomly generated cohorts were designed to appear statistically 
indistinguishable but to have different baseline ASCVD risks, thereby being less 
likely to respond differently to intervention. Lastly we applied the tool to four real-
world clinic cohorts. In this last application we also extrapolated the effects of non-
pharmacologic interventions to determine which intervention is the best for any given 
cohort. 
Model: Baseline 10-Year ASCVD Risk and Risk Change Equations) At a 
decrease of 80 mmHg the average decrease in normalized aggregate risk was 7.2 
ASCVD events per 1,000 patients with a standard deviation of 1.1 events. 
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Figure 4. Variances in sensitivity to systolic blood pressure decreases for 
randomly generated cohorts. Each color represents a different randomly generated 
cohort. Decreases in normalized aggregate risk of ASCVD events are displayed in 
expected ASCVD events per 1,000 patients in the next 10 years. 
Figure 5 shows the decrease in normalized aggregate risk for all ten cohorts 
resulting from smoking cessation interventions. The smoking cessation interventions 
ranged in probability of cessation from 0.01 to 1.00. With a probability of 1.00 the 
average decrease in normalized aggregate risk was 8.7 ASCVD events per 1,000 
patients with a standard deviation of 1.4 events. 
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Figure 5. Variances in sensitivity to smoking cessation interventions for 
randomly generated cohorts. Each color represents a different randomly generated 
cohort. Decreases in normalized aggregate risk of ASCVD events are displayed in 
expected ASCVD events per 1,000 patients in the next 10 years. 
Application: Comparison of Demographic Data for Clinic Cohorts 
Across all four clinic cohorts, patients with missing data were on average 
younger by about two years (Table 4a and 4b). For three of the clinics cohorts there 
were statistically significant differences in race distributions with a higher percentage 
of black patients among those included compared to those excluded for missing 
data. In three clinic cohorts, the average systolic blood pressure was higher among 
those included compared to those excluded for missing data. Across all cohorts 
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there was higher prevalence of diabetes mellitus among patients included in the 
study compared to those with missing data.  
Table 4a and 4b. Table comparing the demographic information for patients 
included in the final study versus patients with missing data who were excluded from 
the study. Race and ethnicity categories are set by the options available in the EHR. 
P-values for continuous variables obtained via student’s T-test. P-values for 
categorical variables obtained using Chi Square Test of Independence. P-values 







Number	of	Patients	 1131	 2653	 	 1461	 734	 	
Average	Age	(years)	 55.7	 53.0	 <0.001	 56.1	 53.9	 <0.001	
Gender	 	 	 0.277	 	 	 0.541	
Male	(%)	 41.1%	 39.2%	 	 38.5%	 39.9%	 	
Female	(%)	 58.9%	 60.8%	 	 61.5%	 60.1%	 	
Race	 	 	 <0.001	 	 	 0.002	
Asian	(%)	 1.1%	 1.5%	 	 0.5%	 1.1%	 	
Black	(%)	 41.8%	 36.0%	 	 52.1%	 45.4%	 	
Hispanic	(%)	 1.1%	 0.2%	 	 0.6%	 0.5%	 	
White	(%)	 0.1%	 25.3%	 	 20.9%	 28.2%	 	
Other/Unknow
n	(%)	 27.0%	 36.1%	 	 25.8%	 24.8%	 	
Ethnicity	 	 	 0.001	 	 	 0.090	
Hispanic	(%)	 25.1%	 30.5%	 	 23.8%	 20.4%	 	
Non-Hispanic	
(%)	 74.9%	 69.5%	 	 76.2%	 79.6%	 	
Current	Smokers	(%)	 14.1%	 16.1%	 0.143	 30.9%	 37.1%	 0.005	
Diabetes	Prevalence	(%)	 43.3%	 25.6%	 <0.001	 42.5%	 21.5%	 <0.001	
Average	Systolic	Blood	
Pressure	(mmHg)	 129.8	 128.0	 <0.001	 131.8	 130.6	 0.102	
Average	Total	Cholesterol	
(mg/dL)	 178.0	 176.6	 0.783	 184.2	 195.4	 0.007	
Average	HDL	Cholesterol	










Number	of	Patients	 41	 88	 	 1925	 1046	 	
Average	Age	(years)	 51.5	 50.3	 0.458	 59.0	 57.6	 <0.001	
Gender	 	 	 0.588	 	 	 0.513	
Male	(%)	 48.8%	 55.7%	 	 41.6%	 42.9%	 	
Female	(%)	 51.2%	 44.3%	 	 58.4%	 57.1%	 	
Race	 	 	 0.128	 	 	 <0.001	
Asian	(%)	 0.0%	 0.0%	 	 3.7%	 4.2%	 	
Black	(%)	 2.4%	 3.4%	 	 18.8%	 10.6%	 	
Hispanic	(%)	 19.5%	 4.5%	 	 0.7%	 0.5%	 	
White	(%)	 2.4%	 5.7%	 	 66.8%	 76.4%	 	
Other/Unknown	
(%)	 75.6%	 86.4%	 	 9.8%	 8.2%	 	
Ethnicity	 	 	 0.957	 	 	 0.009	
Hispanic	(%)	 87.8%	 86.4%	 	 10.1%	 7.2%	 	
Non-Hispanic	
(%)	 12.2%	 13.6%	 	 89.9%	 92.8%	 	
Current	Smokers	(%)	 7.3%	 15.9%	 0.287	 9.1%	 8.7%	 0.772	
Diabetes	Prevalence	(%)	 17.1%	 12.5%	 0.671	 22.6%	 12.0%	 <0.001	
Average	Systolic	Blood	
Pressure	(mmHg)	 125.9	 119.4	 0.012	 128.0	 126.8	 0.016	
Average	Total	Cholesterol	
(mg/dL)	
193.7	 195.0	 0.904	 190.3	 189.5	 0.579	
Average	HDL	Cholesterol	
(mg/dL)	 52.0	 57.6	 0.225	 60.2	 55.9	 <0.001	
 
Application: Modeled Risk Reduction among Actual Clinic Cohorts  
The baseline normalized aggregate risk of the SRC cohort was 117.3 ASCVD 
events per 1,000 patients in the next 10 years. For the HAVEN cohort it was 55.2 
and for the PCC and YIMA cohorts it was 104.6 and 100.8 respectively. For an 
intervention targeting reduction of systolic blood pressure, 158 patients from PCC, 
251 from SRC, 4 from HAVEN and 183 from YIMA met criteria for hypertension 
treatment based on age and systolic blood pressure. The effects of interventions 
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targets ranging from a decrease of 0 mmHg to 80 mmHg for each cohort is shown in 
Figure 6. 
	
Figure 6. Variances in sensitivity to systolic blood pressure decreases for the 
four clinic cohorts. The clinic cohorts shown are PCC (Blue), SRC(Green), HAVEN 
(Brown), and YIMA (Black). Decreases in normalized aggregate risk of ASCVD 
events are displayed in expected ASCVD events per 1,000 patients in the next 10 
years. 
For an intervention on total cholesterol, 557 patients from PCC, 822 from 
SRC, 9 from HAVEN and 901 from YIMA meet criteria for treatment based on a 
baseline ASCVD risk score greater than 7.5%. The effects of interventions targets 




Figure 7. Variances in sensitivity to total cholesterol decreases for the four 
clinic cohorts. The clinic cohorts shown are PCC (Blue), SRC(Green), HAVEN 
(Brown), and YIMA (Black). Decreases in normalized aggregate risk of ASCVD 
events are displayed in expected ASCVD events per 1,000 patients in the next 10 
years. 
An increase in HDL cholesterol was applied broadly to all patients in all clinic 
cohorts. The effects of intervention targets ranging from an increase of 0 mg/dL to 
100 mg/dL in HDL cholesterol for each cohort is shown in Figure 8. 
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Figure 8. Variances in sensitivity to HDL cholesterol increases for the four 
clinic cohorts. The clinic cohorts shown are PCC (Blue), SRC(Green), HAVEN 
(Brown), and YIMA (Black). Decreases in normalized aggregate risk of ASCVD 
events are displayed in expected ASCVD events per 1,000 patients in the next 10 
years. 
Among the four cohorts the smoking prevalence was 14.1%, 30.9%, 7.3%, 
and 9.1% for the PCC, SRC, HAVEN and YIMA clinic cohorts respectively. The 
effects of smoking cessation interventions with probabilities ranging from 0 to 1.0 for 




Figure 9. Variances in sensitivity to smoking cessation interventions for the 
four clinic cohorts. The clinic cohorts shown are PCC (Blue), SRC(Green), HAVEN 
(Brown), and YIMA (Black). Decreases in normalized aggregate risk of ASCVD 
events are displayed in expected ASCVD events per 1,000 patients in the next 10 
years. 
Application: Secondary Analysis of Clinic Cohorts 
A secondary analysis of the clinic cohorts was performed to determine if using 
the last known blood pressure instead of the one-year average significantly changed 
any of the results. The baseline normalized aggregate risk for all clinic cohorts were 
within 1 ASCVD event of the previously calculated baseline using the average 
systolic blood pressure. The rest of the analysis remained mostly unchanged except 
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for a slightly different sensitivity curve to systolic blood pressure interventions, 
shown in Figure 10. 
	
Figure 10. Variances in sensitivity to systolic blood pressure decreases for 
the four clinic cohorts using the last known systolic blood pressure instead of the 
average. The clinic cohorts shown are PCC (Blue), SRC(Green), HAVEN (Brown), 
and YIMA (Black). Decreases in normalized aggregate risk of ASCVD events are 
displayed in expected ASCVD events per 1,000 patients in the next 10 years. 
Application: Effect of Quality Improvement Interventions on the Clinic 
Cohorts 
A total of 38 different Cochrane Review articles describing lifestyle 
interventions for direct or indirect ASCVD prevention were found. Twelve described 
diet and exercise interventions, eight described interventions on blood pressure 
 35 
alone, fourteen described different methods of smoking cessation, and one 
described effects of statin therapy.  
Of the twelve diet and exercise interventions, seven had statistically 
significant effects on at least one of the modifiable risk factors. These seven 
interventions are described below. 
• Usinger et al. (2012) described the use of fermented milk to lower 
systolic blood pressure on a general population by 2.45 mmHg. This 
effect was applied to all patients in all clinic cohorts who had a baseline 
systolic blood pressure above 110 mmHg.8 
• Rees et al. (2013) described the use of general dietary advice given by 
providers. As compared to no advice, this intervention was found to 
have statistically significant effects on total cholesterol and systolic 
blood pressure on a general population. For male patients, total 
cholesterol decreased by 9.2 mg/dL, but no significant effect was found 
for women. For patients with a high risk of cardiovascular disease, the 
decrease in systolic blood pressure was 2.95 mmHg, but there was no 
statistically significant effect for the general population. High risk was 
not well defined in Rees et al. and therefore a cutoff of 7.5% per 
individual patient was used for the purpose of our analysis. A lower 
bound of 80 mg/dL for total cholesterol and 110 mmHg was used for 
systolic blood pressure interventions.9 
• Hartley et al. (2013) reviewed the effects of interventions to increase 
fruit and vegetable consumption. Although studies which provided 
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fruits and vegetables were included in the review, they were found to 
have no benefit across all variables compared to interventions which 
focused on advice only. Among a general population, advice to 
increase fruit and vegetable consumption was found to have a 3.0 
mmHg decrease in systolic blood pressure. We used the lower bound 
of 110 mmHg for this intervention.10 
• Rees et al. (2013) reviewed the effects of a Mediterranean diet on 
many risk factors. It was found that among a general population 
adhering to a Mediterranean diet, total cholesterol was decreased by 
6.2 mg/dL. A lower bound of 80 mg/dL was utilized when applying this 
intervention to the clinic cohorts.11 
• Ebrahim et al. (2011) compiled the results of multifactorial 
interventions for the primary prevention of ASCVD. These interventions 
consisted of counseling and education. They found that these 
interventions had no benefit for a general population but had significant 
beneficial effects for patients with hypertension or diabetes mellitus. 
Therefore, this intervention was only applied to those patients with 
either hypertension or diabetes within our clinic cohorts. Total 
cholesterol was reduced by 2.7 mg/dL, while systolic blood pressure 
was decreased by 2.74 mmHg for those not on antihypertensive drugs 
while it was decreased by 3.89 mmHg for patients on antihypertensive 
drugs. Smoking cessation counseling and education resulted in a 15% 
reduction in smoking prevalence.12 
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• Adler et al. (2013) studied the effects of a reduced salt diet on the 
general population. The advice to decrease dietary salt had a 4.14 
mmHg decrease in systolic blood pressure among patients with 
hypertension but no effect on normotensive patients.13 
• Siebenhofer et al. (2011) covered the effects of dietary interventions 
aimed at weight reduction on ASCVD prevention. The only significant 
effect was on systolic blood pressure with an average decrease of 4.49 
mmHg among hypertensive patients. A lower bound of 110 mmHg was 
again used on the intervention.14 
Of the eight Cochrane Reviews found to target hypertension as a primary 
prevention strategy for ASCVD, only three were included in this study. Reasons for 
exclusion were that they were either based on pharmacotherapies, which is out of 
the scope of this study, or did not include outcomes on systolic blood pressure. 
Since these interventions were focused on hypertension, the effects were applied 
only to patients who had a systolic blood pressure above 140 mmHg if they were 
under 60 years of age or 150 mmHg for 60 or more years of age, or patients who 
were already in treatment for hypertension. These interventions are described 
below. 
• Glynn et al. (2010) reviewed the effects of multiple types of 
interventions including self-monitoring, health professional led care, 
organizational interventions, and appointment reminders, respectively. 
Organizational interventions were further described as interventions 
that aimed to improve the delivery of care. One example includes the 
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Hypertension Detection and Follow-Up Program from 1979.15 These 
interventions reduced systolic blood pressure by 2.53 mmHg, 2.52 
mmHg, 6.00 mmHg and 4.56 mmHg, respectively. Patient and 
physician education were also studied independently but neither was 
found to have a significant effect on systolic blood pressure.16 
• Dickinson et al. (2006) described the used of calcium supplements for 
the treatment of hypertension. For hypertensive patients with a 
baseline systolic blood pressure above 145 mmHg, calcium 
supplements were shown to decrease systolic blood pressure by 2.49 
mmHg.17  
• Dickinson et al. (2008) compiled the effects of relaxation techniques 
on hypertensive patients. These techniques were found to have a 5.5 
mmHg decrease in systolic blood pressure.18 
The fourteen Cochrane Reviews found describing smoking cessation 
interventions all reported the odds ratio as its final outcome. The odds ratio was not 
possible to use in this model as we would need to know the smoking cessation rate 
without an intervention. Therefore, smoking cessation interventions were omitted 
from this part of the study. Similarly, the one intervention found specifically for 
lowering of total cholesterol was pharmacologic in nature and out of the scope of this 




Table 5. Summary of interventions chosen for application from Cochrane 
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Usinger	et	al.,	2012	(BP)	 All	patients	 	 	 -2.45	 	
Advice	to	eat	F&V	from	
Hartley	et	al.,	2013	(BP)	 All	patients	 	 	 -3.00	 	
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hypertension	 	 	 -5.50	 	
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Table 6. Estimated changes in normalized aggregate risk of various 
interventions. Each of the interventions listed has an effect on systolic blood 
pressure, total cholesterol, HDL cholesterol or smoking status. Data on the effect 
size was pulled from Cochrane Reviews. The baseline risk and the changes are 
shown in expected ASCVD events per 1,000 patients in the next 10 years. Dark 
green shading indicates the interventions with the greatest positive outcome for each 
clinic cohort. The HAVEN clinic with its lower baseline risk appears to respond more 




PCC	 SRC	 HAVEN	 YIMA	
Baseline	risk	(events	per	1,000	
patients)	 104.60	 117.33	 55.21	 100.80	
Diet	Advice	from	Rees	et	al.,	2013	
(Chol	and	BP)	 -4.71	 -4.72	 -2.02	 -3.77	
Fermented	Milk	from	Usinger	et	al.,	
2012	(BP)	 -3.25	 -3.42	 -1.32	 -2.53	
Advice	to	eat	F&V	from	Hartley	et	al.,	
2013	(BP)	 -3.97	 -4.19	 -1.61	 -3.10	
Mediterranean	Diet	from	Rees	et	al.,	




-4.63	 -5.39	 -0.86	 -2.06	
Low	Salt	Diet	from	Adler	et	al.,	2013	
(BP)	 -2.20	 -2.45	 -0.79	 -1.52	
Weight	Reduction	Diet	from	
Siebenhofer	et	al.,	2011	(BP)	 -4.53	 -4.84	 -0.60	 -2.88	
Self-Monitoring	of	HTN	from	Glynn	et	
al.,	2010	(BP)	 -2.57	 -2.74	 -0.34	 -1.63	
Health	Professional	Led	Care	of	HTN	
from	Glynn	et	al.,	2010	(BP)	 -2.56	 -2.73	 -0.34	 -1.63	
Organizational	Interventions	on	HTN	
from	Glynn	et	al.,	2010	(BP)	 -6.00	 -6.44	 -0.79	 -3.84	
Appointment	Reminders	on	HTN	from	
Glynn	et	al.,	2010	(BP)	 -4.60	 -4.91	 -0.61	 -2.93	
Calcium	Supplements	for	HTN	from	
Dickinson	et	al.,	2009	(BP)	 -0.99	 -1.51	 -0.21	 -0.66	
Relaxations	for	HTN	from	Dickinson	et	




The results from our simulations with randomly generated cohorts with 
indistinguishable demographics demonstrated that there is a large amount of 
potential variance in baseline normalized aggregate risk of ASCVD and response to 
interventions. As a proof of concept these results support the utility of the tool we 
have created to analyze clinic populations. These results were replicable when 
applied to four real clinic cohorts. The ASCVD risk reduction from a given 
intervention was dependent on baseline normalized aggregate risk and average 
value of the modified risk factor. Furthermore, the effects of lifestyle interventions on 
ASCVD risk could be modeled through their effects on the modifiable risk factors by 
our tool. The intervention with the highest ASCVD risk reduction was not the same 
across all cohorts. 
The 10,000 randomly generated cohorts with the same demographic 
characteristics had significantly different baseline normalized aggregate risk. 
Importantly, this demonstrates that population averages should not be used in the 
10-year ASCVD risk calculator to estimate the risk of a population. Doing so would 
result in inaccurate prediction of normalized aggregate risk. Further, when we tested 
the response of these randomly generated cohorts to single variable interventions, 
the response curves indicated that there is decreasing marginal risk reduction to 
interventions aiming to reduce total cholesterol, HDL cholesterol, and systolic blood 
pressure. These patterns were also observed on the four real clinic populations with 
the addition of the fact that response to the same interventions differed by baseline 
risk. In the case of total cholesterol and systolic blood pressure, we observed that 
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cohorts responded differently to interventions on the same risk factor but that these 
relationships may change depending on the effect size of said intervention. In other 
words, the effect of interventions on systolic blood pressure will not always be better 
for cohort A compared to cohort B but that this relationship depends on the amount 
of change in systolic blood pressure. 
Chu et al. (2016) demonstrated that the use of simulation with the 10-year 
ASCVD risk calculator has a role in choosing high-yield primary prevention 
interventions.2 They created hypothetical patients of different characteristics and 
estimated the effect of different interventions on each of these patients. That study 
created a chart that would allow a provider to prioritize an intervention for any given 
patient based on the expected ASCVD risk decrease. However, their models are 
limited to individual patients and not whole populations. Our results suggest that 
similar methods are applicable to whole populations. Franco et al. (2007) used 
similar statistical techniques to our model using the Framingham Risk Score.3 They 
concluded that smoking-cessation was the most cost-effective intervention for the 
primary prevention of ASCVD within the Framingham cohorts. With our tool, we 
aimed to combine the principles of these two papers to guide clinics in choosing the 
best primary prevention intervention(s) for their specific patient population. 
The effect of thirteen different non-pharmacologic evidence-based 
interventions on systolic blood pressure, total cholesterol, HDL cholesterol and/or 
smoking prevalence had different effects on ASCVD risk across four clinic cohorts. 
According to our model, the highest yield intervention for the HAVEN clinic was to 
implement a diet advice program as described in Rees at al., while all the other 
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clinics would benefit most from an organizational quality improvement project to 
address hypertension as described in Glynn et al.9,16 However, the organizational 
interventions described in Glynn et al. varied in type and effect size making the 
effects less reproducible. The only shared commonality is that they “aimed to 
improve the delivery of care.” Another high yield intervention among three of the 
cohorts was a weight reducing diet as described by Siebenhofer et al. (2011)14 It is 
worth noting that this intervention was not limited to advice only and may require a 
great amount of resources to fully implement. Therefore, any clinic using the tool to 
choose an intervention could face a choice between these two difficult to implement 
options. However, they approach this decision with more knowledge of the expected 
outcomes. Alternatively, other interventions could be relatively easy to implement 
and have a great impact, such as diet advice as described by Rees et al.9  
The HAVEN clinic had the most significantly different population among the 
four clinics. The patients were younger, there were far more patients who identified 
as Hispanic and the baseline normalized aggregate ASCVD risk was significantly 
lower. As such it was not surprising that its responses to the many non-
pharmacologic interventions were also different from the other three clinics. At the 
HAVEN clinic, interventions that target the general population were much more 
successful than interventions that target high risk populations (i.e. patients with 
hypertension). This is in contrast to the three other clinics where the opposite was 
true. 
Another factor clinics may consider is the number of patients involved in each 
intervention. The fruits and vegetable dietary interventions were applied to entire 
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clinic cohorts whereas the hypertension interventions described by Glynn et al. were 
only applied to hypertensive patients. So providers will have a tradeoff between high 
yield interventions on a few high risk patients or more broad interventions with 
similar results on the overall ASCVD risk. 
The tool we have created allows the ACC/AHA 10-year ASCVD risk calculator 
to be used as a metric to monitor and reduce ASCVD risk in a clinic cohort. Clinic 
providers and/or administrators will be able to use the tool to allocate their limited 
resources to the ASCVD prevention strategy with the highest predicted impact 
based on quantitative predictions. Ultimately we envision such a tool being used by 
clinics to select and monitor primary preventions strategies for ASCVD, similarly to 
how a physician already uses the tool to guide preventions strategies at the 
individual patient level. For example, a clinic hires a new health educator and they 
are faced with choosing a new project for this employee: smoking cessation, or 
hypertensive management education. While it would be simple choice if everyone in 
the clinic cohort is a smoker but there are no patients with hypertension (or vice 
versa), the choice becomes more complicated if that is not the case. The current 
literature does not offer a threshold prevalence above which a smoking cessation 
intervention becomes more efficient at reducing AVCD risk than hypertension 
education; we discovered that the change in risk varies significantly by cohort. The 
tool we have created would be able to tell the health educator which of these 
interventions would have the greatest impact on the population of this clinic. After 
initiation of the intervention, the tool can also be used to continuously monitor the 
ASCVD risk in the community for continuing quality improvements cycles. 
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At a larger scale, hospitals are now mandated to conduct community health 
assessments and identify areas of need.19 By incorporating data from the EHR and 
community health assessments, the tool we created can model the effects of 
interventions on whole communities. This data can be utilized by hospitals or public 
health departments to supplement community needs assessments and guide 
policy/programs.19 Community leaders would, for example, be able to prioritize their 
resources to an exercise campaign or a farmers’ market, depending on the effect 
sizes estimated by our tool. The reports generated by our tool may even be used as 
supporting evidence in grant application or project proposals. The 2003 AHA Guide 
for Improving Cardiovascular Health at the Community Level suggests that 
community based interventions be chosen based solely on the identification of high 
risk groups and/or the feasibility of said interventions (i.e. the prevalence of smoking, 
and the feasibility of an ad campaign).20 In this guideline, efficacy of interventions at 
the community level is not accounted for, however our tool can supplement this 
decision-making process by providing quantitative efficacy predictions. 
Limitations of This Study 
This study has important limitations. Our study relies on assumptions made 
for our statistical prediction method. The first assumption is that all factors except the 
one being modified remain unchanged during the interventions. For example, we 
assume that while patients participate in an intervention on blood pressure that their 
age, smoking status, diabetes diagnosis and cholesterol levels remain unchanged. 
Another assumption in our study is that effects described in Cochrane reviews 
will be the same among the patient populations in our study. There are likely factors 
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beyond our model that will affect the results and therefore the observed ASCVD risk 
reduction observed will also differ.  
Another set of assumptions are the lower boundaries of 110 mmHg and 80 
mg/dL used for systolic blood pressure and total cholesterol, respectively. Here we 
assumed that patients who started above these lower boundaries would not be able 
to go below it. This was meant to simulate the way real patients may respond to 
interventions and the natural limits of any intervention. Though the boundaries were 
chosen based on clinical experience, the real response by patients may vary. 
Our included sample may have been biased. The patients with missing data 
across all clinics had at least one statistically significant difference in their 
demographics, suggesting systematic differences between these populations. For 
example, patients with missing data tended to be younger in all clinics, likely 
because they did not receive cholesterol screening or did not return to clinic. Among 
three of the four clinics, patients with missing data were less likely to have a 
diagnosis of diabetes mellitus. This likely reflects either not enough follow up to 
establish the diagnosis or a closer follow up of patients who do have the diagnosis. 
These differences indicate that patients excluded from analyses may have different 
baseline risk and therefore may respond differently to the interventions. This also 
brings up the fact that patient cohorts are not static and that new patients will join the 
panel while other patients leave. These factors are not accounted for in our 
estimates. 
Lastly, we do not account for any of the other positive or negative effects of 
any intervention outside of the ASCVD risk factors or on overall ASCVD risk. In the 
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case of total cholesterol reduction for example, it has been shown that using statin 
therapy has an effect on ASCVD risk beyond what is accounted for by total 
cholesterol reduction.21 
Next Steps 
Ultimately, we aim to provide clinicians with the tools necessary to choose the 
most efficient ASCVD prevention strategy. Though this application is currently only 
able to identify the goals of therapy and expected impact of evidence-based 
interventions, in the future it can be adapted to make recommendations using cost 
efficiency data and/or cost estimates from the literature. For example, Pandya et al. 
(2015) built a model that estimated cost-effectiveness for different statin therapy 
thresholds using known data on their efficiency, their cost and the ASCVD 10-year 
risk calculator.5 We envision statistical models similar to those used in Pandya et al. 
2015 except applied at the clinic population level, using real-time data and across all 
modifiable risk factors.5 
Furthermore, the feasibility and adoption of such a tool remains to be 
elucidated. We plan to perform a qualitative study to assess primary care clinic 
directors’ ease of use, interpretation and applicability of the application. We then aim 
to conduct a controlled trial involving several clinics randomized to use the tool or to 
use usual quality improvement strategies to decrease ASCVD events. The objective 
of such a trial would be to determine if the strategies and goals suggested by the 
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